• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Bristol-Myers Continues to Show Bottoming Price Action on the Charts

Let's check out the charts of BMY.
By BRUCE KAMICH
Jun 24, 2019 | 12:20 PM EDT
Stocks quotes in this article: BMY, CELG

Bristol-Myers Squibb  (BMY)  is in the news Monday as they plan the sale of their plaque psoriasis and psoriatic arthritis drug Otezla to win FTC approval for their $74 billion Celgene Corp. (CELG) deal. Let's check out the charts of BMY.

In this daily bar chart of BMY, below, we can see that prices sold off sharply in October and made a lower low in early January. A lower close was made in April but not a lower intraday low.

Stepping back a bit and looking at the chart we can see that dips below $46 look like they have found buying interest. Prices are back down to $46 but it remains to be seen if investors of BMY will again show up as buyers below $46. BMY is trading back below the rising 50-day moving average line. This drug company has been below it's declining 200-day line since the middle of October.

The daily On-Balance-Volume (OBV) line shows a mostly bearish trend from October signaling aggressive selling. The Moving Average Convergence Divergence (MACD) oscillator has spent most of the last year below or hugging the zero line.

In this weekly bar chart of BMY, below, we can see that prices are below the declining 40-week moving average line. Today's price action is not plotted but we can imagine a decline to $46.

The weekly OBV line is weak and the weekly MACD oscillator is not showing much in terms of trend strength.

In this Point and Figure chart of BMY, below, we can a large potential base pattern with an upside price projection of $57.46.

Bottom line strategy: It looks like BMY is trying hard to bottom. We have an upside price target from the Point and Figure chart but their pending acquisition may be keeping investors sidelined. A trade at $50.01 will be bullish.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Mergers and Acquisitions | Investing | Markets | Stocks | Technical Analysis | Trading | Pharmaceuticals

More from Investing

To Be a Great Trader, Plan on Losing Money

James "Rev Shark" DePorre
Dec 14, 2019 10:00 AM EST

Losses are simply a function of the trading process and are not an indication of failure.

A Quiet Conclusion to a Dramatic and Contentious Issue

James "Rev Shark" DePorre
Dec 13, 2019 4:24 PM EST

This market has such a positive brew that has to make you at least a little apprehensive.

Facebook Investors Shouldn't Panic Over Reports the FTC Wants an Injunction

Eric Jhonsa
Dec 13, 2019 2:44 PM EST

Recent reports have heightened fears that the FTC will push for Facebook to be broken up. But any such effort is by no means guaranteed to succeed...and might not be a disaster for shareholders even if it did.

Currencies Will Eventually Matter for Crude Oil and Other Commodities

Carley Garner
Dec 13, 2019 2:00 PM EST

If the currency markets come back to life it will put oil back on the trading screens of speculators.

My Trade Idea for Oracle

Stephen Guilfoyle
Dec 13, 2019 12:30 PM EST

ORCL is competing for the business to business cloud, obviously a tough space.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EST BOB LANG

    Banking a Big Winner in SRPT, Rolling Up

    Nov. 20 here on the CC, I mentioned buying some Ma...
  • 10:36 AM EST GARY BERMAN

    Fibocall: How High Can Crude Go?

    On crude: I am looking for higher, but please b...
  • 08:20 AM EST BOB LANG

    Webinar Time - Talkin' Calendars, Butterflys

    join me later today after the market close as we t...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login